Literature DB >> 1124664

Intrauterine death and circulating anticoagulant ("antithromboplastin").

I M Nilsson, B Astedt, U Hedner, D Berezin.   

Abstract

A report is presented of a young, otherwise apparently healthy, woman who had three pregnancies which for some unknown reason terminated in intrauterine death (macerated foetuses). During the third pregnancy a coagulation defect was diagnosed, which was characterized by prolonged coagulation times and prolonged one-stage prothrombin time. This defect disappeared after the end of the pregnancy, but returned during the fourth pregnancy. This time a circulating anticoagulant was found, which inhibited the action of thromboplastin. The values found for the various coagulation factors were normal. The anticoagulant titre rose during the pregnancy from 1/2 to 1/10. Leucocyte agglutinating as well as lymphocytotoxic antibodies directed against the husband's cells were demonstrated in the patient during the pregnancy. In this case, by passage of cell fragments and thromboplastic substances to the mother, the foetus had probably induced the development of antibodies against the foetal tissues. The foetus may be regarded as an incompatible transplant. The fourth pregnancy was terminated by caesarean section in the 34th week. The child weighed 1440 g and, after three exchanges of blood, did very well. The placenta was severely infarcted. It is postulated that the development of antithromboplastin during pregnancy may be a contributory cause of intrauterine death.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1124664     DOI: 10.1111/j.0954-6820.1975.tb04897.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  31 in total

1.  For the want of an heir: the obstetrical history of Queen Anne.

Authors:  H E Emson
Journal:  BMJ       Date:  1992-05-23

Review 2.  Pregnancy and antibodies to phospholipids.

Authors:  M J Walport
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

Review 3.  Evaluation of the obstetrical risks of the antiphospholipid syndrome and therapeutic management.

Authors:  P Edelman; A M Rouquette
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

4.  Anti-phospholipid antibodies in syphilis and a thrombotic subset of SLE: distinct profiles of epitope specificity.

Authors:  C B Colaço; D K Male
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

5.  Fetal loss treatment in patients with antiphospholipid antibodies.

Authors:  J Ordi; J Barquinero; M Vilardell; R Jordana; C Tolosa; A Selva; E Genover
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

6.  Spontaneous abortion is associated with elevated systemic C5a and reduced mRNA of complement inhibitory proteins in placenta.

Authors:  M Banadakoppa; M S Chauhan; D Havemann; M Balakrishnan; J S Dominic; C Yallampalli
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

7.  Prevalence of anticardiolipin antibodies in pregnancies with history of repeated miscarriages.

Authors:  Ligia Cosentino Junqueira Franco Spegiorin; Eloísa A Galão; Lúcia Buchalla Bagarelli; Antonio Hélio Oliani; José Maria Pereira de Godoy
Journal:  Open Rheumatol J       Date:  2010-08-26

8.  The testosterone hypothesis: Assessment since Geschwind and Behan, 1982.

Authors:  A M Galaburda
Journal:  Ann Dyslexia       Date:  1990-01

9.  Screening for lupus anticoagulant and anticardiolipin antibodies in women with fetal loss.

Authors:  M D Creagh; R G Malia; S M Cooper; A R Smith; S L Duncan; M Greaves
Journal:  J Clin Pathol       Date:  1991-01       Impact factor: 3.411

Review 10.  Anticoagulation in management of antiphospholipid antibody syndrome in pregnancy.

Authors:  Michael D Lockshin
Journal:  Clin Lab Med       Date:  2013-04-19       Impact factor: 1.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.